

Please amend the claims as follows:

1-4. (Canceled)

5. (Previously presented) An isolated laminin α 5 polypeptide, consisting of the amino acid sequence of SEQ ID NO:2.

6-8. (Canceled)

9. (Currently amended) [The] **Isolated** [isolated] recombinant laminin 10 [of claim 7] comprising:

a first chain comprising a polypeptide at least **80%** [70%] identical to [one or more] a polypeptide sequence [sequences selected from the group consisting] of SEQ ID NO:2 [, and SEQ ID NO:4];

a second chain comprising a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12; and

a third chain comprising a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20;

wherein the first, second, and third chains are assembled into recombinant laminin 10.

10-16. (Canceled)

17. (Currently amended) Isolated recombinant laminin 10 [isolated according to] produced by a method comprising

a. providing recombinant laminin 10-expressing host cells, wherein the recombinant laminin 10 comprises:

a first chain comprising a polypeptide at least **80%** [70%] identical to [one or more] a polypeptide sequence[s selected from the group consisting] of SEQ ID NO:2 [, and SEQ ID NO:4];

a second chain comprising a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12; and

a third chain comprising a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20;

wherein the first, second, and third chains are assembled into recombinant laminin 10;

b. growing the cells in cell culture medium under conditions to stimulate expression of the recombinant laminin 10 chains;

c. passing the cell culture medium through an affinity chromatography column, wherein the column contains a compound that binds to the recombinant laminin 10;

d. washing the affinity column to remove unbound materials; and

e. eluting the bound recombinant laminin 10 from the column.

18-22. (Canceled)

23. (Currently amended) A pharmaceutical composition comprising:

a) the isolated laminin 10 of claim 9 [6]; and

b) a pharmaceutically acceptable carrier.

24 (Canceled)

25 (Previously presented) The isolated laminin 10 of claim 9 wherein the first chain comprises a polypeptide at least 90% identical to the polypeptide sequence of SEQ ID NO:2.

26 (New) The isolated laminin 10 of claim 9 wherein the first chain comprises the polypeptide sequence of SEQ ID NO:2.

27. (New) The isolated laminin 10 of claim 9 wherein the second chain comprises a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:6 and SEQ ID NO:8.

28 (New) The isolated laminin 10 of claim 9 wherein the second chain comprises a polypeptide at least 80% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:6 and SEQ ID NO:8.

29 (New) The isolated laminin 10 of claim 25 wherein the second chain comprises a polypeptide at least 90% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:6 and SEQ ID NO:8.

30 (New) The isolated laminin 10 of claim 26 wherein the second chain comprises a polypeptide sequence selected from the group consisting of SEQ ID NO:6 and SEQ ID NO:8.

31. (New) The isolated laminin 10 of claim 27 wherein the third chain comprises a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:14 and SEQ ID NO:16.

32 (New) The isolated laminin 10 of claim 28 wherein the third chain comprises a polypeptide at least 80% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:14 and SEQ ID NO:16.

33 (New) The isolated laminin 10 of claim 29 wherein the third chain comprises a polypeptide at least 90% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:14 and SEQ ID NO:16.

34 (New) The isolated laminin 10 of claim 30 wherein the third chain comprises a polypeptide sequence selected from the group consisting of SEQ ID NO:14 and SEQ ID NO:16.

35. (New) A pharmaceutical composition comprising:

- a) the isolated laminin 10 of any one of claims 26-34; and**
- b) a pharmaceutically acceptable carrier.**